Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T19:43:32.158Z.
Calculation as of: 2026-10-06T19:43:32.158Z.
Quote observation: 2026-10-06T19:40:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f2b785bc55096390182f69d3a0e2d020d3bb9b84e75505e860cfcb21a76503d6
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
TriSalus Life Sciences, Inc.
Market Cap
$266.00M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$264.03M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$263.97M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$269.11M
Price/OCF Ratio
N/A
TTM Avg
10.26
3Y Avg
12.21
5Y Avg
13.91
Market Cap
$268.41M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$260.94M
Price/OCF Ratio
N/A
TTM Avg
64.10
3Y Avg
34.63
5Y Avg
150.74
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TriSalus Life Sciences, Inc. (TLSI) | $266.00M | N/A | N/A | N/A | N/A |
| Fate Therapeutics, Inc. (FATE)vs › | $267.50M | N/A | N/A | N/A | N/A |
| Treace Medical Concepts, Inc. (TMCI)vs › | $264.03M | N/A | N/A | N/A | N/A |
| Scribe Therapeutics Inc. (SCTX)vs › | $262.31M | N/A | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $263.97M | N/A | N/A | N/A | N/A |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $269.11M | N/A | 10.26 | 12.21 | 13.91 |
| SAB Biotherapeutics, Inc. (SABS)vs › | $268.41M | N/A | N/A | N/A | N/A |
| OraSure Technologies, Inc. (OSUR)vs › | $260.94M | N/A | 64.10 | 34.63 | 150.74 |
| Palisade Bio, Inc. (PALI)vs › | $261.24M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $262.00M | N/A | 134.67 | 134.67 | 134.67 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
